A research subject starts an SR-T3 protocol, titrates carefully over several weeks, and gets labs back showing Free T3 at 2.8 pg/mL. The lab report prints "normal" next to that number - it falls within the reference range. And yet basal body temperature remains below 97.8°F, fatigue has not resolved, and the cognitive clarity that was supposed to emerge has not appeared.
This is the central tension in Free T3 interpretation: the lab reference range for Free T3 was built from population averages, not from symptom-resolution data. A value of 2.8 pg/mL is "normal" in the sense that a large slice of the tested population had values in that neighborhood. It does not mean that 2.8 pg/mL represents a level at which thyroid hormone signaling is adequate for that individual.
Research Grade · Discreet Worldwide Shipping
Wilson's SR-T3 Combo Kit
The bioenergetic research community has converged on a different framework for evaluating Free T3 - one that looks at where within the reference range a given value sits, what the concurrent reverse T3 load is doing, and critically, what time the blood draw happened relative to the last dose. The gap between "within normal limits" and "in the range where research subjects report symptom resolution" can be several pg/mL - and that gap explains a substantial portion of the T3 non-response patterns discussed in thyroid research forums.
Research framing. This article reviews Free T3 reference ranges, the bioenergetic research community's positioning framework, and the pharmacokinetic factors that affect measured values. It is not medical advice. T3 products on this site are sold strictly for laboratory research and are not approved for human consumption. See our research-use-only disclaimer.
The Lab Reference Range: What "Normal" Actually Means
Standard Free T3 reference ranges vary somewhat by lab and by the units reported. The most commonly encountered values in US labs:
- US labs (conventional units): 2.0 to 4.4 pg/mL (picograms per milliliter)
- SI units used in Canada, UK, and many international labs: 3.1 to 6.8 pmol/L (picomoles per liter)
These two representations are the same range: to convert pg/mL to pmol/L, multiply by 1.536. So 2.0 pg/mL = 3.07 pmol/L and 4.4 pg/mL = 6.76 pmol/L.
How was this range derived? The standard method for establishing clinical reference ranges is to take a large sample of apparently healthy individuals, measure the marker, and set the 2.5th to 97.5th percentile as the reference range. This means, by construction, that 95% of apparently healthy people fall within the range and 2.5% fall above or below it. There is no symptom-resolution criterion embedded in this method. A person who feels profoundly hypothyroid at 2.2 pg/mL - technically "normal" - does not show up as an outlier by this approach; they are simply counted as part of the population.
The practical consequence is that the lower portion of the "normal" Free T3 range sits close to the upper bound of the clearly hypothyroid population. Research-community surveys and forum data consistently show higher rates of cold intolerance, fatigue, brain fog, hair thinning, and low basal body temperature among research subjects whose Free T3 falls below approximately 3.0 pg/mL, despite that value being within the stated reference range. This is not a surprising finding from a statistical standpoint: the population used to derive the range includes subclinically hypothyroid individuals who have not been identified or treated.
A secondary issue is lab-to-lab variability. Free T3 assays across different laboratory platforms are not perfectly standardized. A value of 3.0 pg/mL from one lab is not necessarily equivalent to 3.0 pg/mL from another. Research subjects comparing labs drawn at different facilities are often comparing values that differ by assay methodology, not by actual serum Free T3. This creates artificial variance in longitudinal tracking and reinforces the case for considering where a value sits within the range rather than treating the absolute number as the sole signal.
The Upper-Third Framework
If the lab reference range for Free T3 spans 2.0 to 4.4 pg/mL (a range of 2.4 pg/mL), the upper third of that range spans approximately 3.6 to 4.4 pg/mL. In SI units, the upper third corresponds to approximately 5.6 to 6.8 pmol/L.
This is the Free T3 zone the bioenergetic research community most commonly targets as the symptom-resolution window. The targeting rationale is not arbitrary. The mechanistic argument draws on thyroid hormone receptor saturation data: at values in the lower third of the reference range, T3 receptor occupancy is submaximal and the competition from reverse T3 (which occupies the same receptor without activating it) is more likely to produce net functional insufficiency. Moving Free T3 to the upper third shifts the saturation balance - more receptor sites are occupied by active T3, and the signal-to-noise ratio against the rT3 background improves.
To be precise about the evidence base: this upper-third positioning is a research-community hypothesis that is mechanistically coherent based on receptor saturation arguments and is consistent with the symptom patterns self-reported in bioenergetic thyroid research forums. It has not been validated against randomized controlled trial outcomes comparing upper-third versus lower-third Free T3 targets. Mainstream endocrinology does not recognize an "optimal" sub-range within the normal reference interval; any value within the stated range is considered adequate. The research community's upper-third framework is a working target, not an established clinical standard.
What the upper-third framework provides practically: a more specific internal target for titration. Instead of stopping dose escalation when Free T3 first enters the reference range, research subjects using this framework continue titrating until Free T3 reaches the upper third - while monitoring body temperature and symptom response as the primary dose-adjustment signals. Labs are used to confirm positioning, not as the sole titration criterion.
Free T3 in Cyclic Wilson's WT3 vs Maintenance Protocols
The distinction between cyclic and maintenance protocol contexts is essential for interpreting Free T3 values, because the two protocols have deliberately different target zones.
Maintenance protocols aim for Free T3 in the upper third of the reference range (3.6-4.4 pg/mL) and stay there. The goal is sustained, physiological-range T3 signaling at the upper end of normal - high enough to saturate receptors adequately, low enough to remain within the standard reference band.
Wilson's WT3 cyclic protocol is built on a fundamentally different premise. The protocol uses sustained-release T3 as the vehicle for clearing reverse T3 dominance, and it works by intentionally pushing Free T3 above the standard reference range during the up-titration phase. During active titration on the WT3 protocol, Free T3 values of 6-8 pg/mL are common; at the protocol's peak dose (typically 75-100 mcg every 12 hours in research-community references), values of 9-12 pg/mL or higher are documented. These values are supraphysiologic relative to the lab reference range - and that is by design.
The mechanism the cyclic protocol exploits is receptor saturation as a DIO3 suppressor. By flooding the T3 receptor pool with active T3, the protocol creates the sustained signaling pressure needed to downregulate the type 3 deiodinase (DIO3) enzyme responsible for producing reverse T3. Suppressing DIO3 activity allows the reverse T3 pool to clear (rT3 has a short half-life of approximately 5 hours), and as rT3 falls, the receptor environment shifts from competitive inhibition toward active signaling. The three-week temperature-sustainment criterion built into the Wilson's protocol corresponds to the window needed for this DIO3 reset to stabilize.
After the cyclic phase is complete and the wean-down is executed, Free T3 drops back toward a maintenance range. The intended post-cyclic state is that the former rT3 dominance pattern has been resolved, and Free T3 in the upper third of the reference range now produces the receptor occupancy that was blocked during the rT3-dominant phase.
For the full step-by-step protocol breakdown including titration schedule, temperature monitoring, and weaning criteria, see The Wilson's T3 Protocol (WT3): A Step-by-Step Guide.
The Pharmacokinetic Argument: When Free T3 Is Measured Matters
This section is not optional context - it is essential for interpreting any Free T3 value drawn while a research subject is on SR-T3.
SR-T3's serum concentration curve peaks at approximately 4 to 6 hours post-dose. This is the Tmax: the moment at which the HPMC matrix has released enough of the embedded liothyronine to reach the highest serum concentration for that dosing interval. A blood draw at the 4-to-6-hour mark captures a value close to the peak. A blood draw at 8-12 hours post-dose captures a declining curve, often 20-40% below the peak value. A draw at 12+ hours represents the trough - the lowest point before the next dose.
These are not interchangeable measurements. A research subject who draws labs at 8 AM after their last dose at 9 PM the prior evening is capturing an approximately 11-hour post-dose value. If that value is 2.9 pg/mL, the peak earlier in the cycle was likely in the 3.5-4.2 pg/mL range. Comparing this trough measurement against the upper-third target of 3.6-4.4 pg/mL leads to the false conclusion that the dose is insufficient, when the actual peak may already be within the target window.
The research-community convention for Free T3 timing has two modes:
- Peak measurement: Blood draw 4-6 hours after the morning SR-T3 dose. This captures the highest serum Free T3 achievable at that dose level and is most useful for assessing whether the dose is reaching the upper-third target.
- Trough measurement: Blood draw 12 or more hours after the last SR-T3 dose (typically the following morning before the first dose). This captures the nadir and is most useful for assessing whether T3 receptor exposure is being maintained through the dosing interval without dropping too low.
Most research subjects and practitioners who draw Free T3 labs do so at a standard morning appointment without accounting for dose timing - producing a value that falls somewhere between peak and trough depending on when they last dosed. That value is valid as a data point, but it cannot be directly compared to a stated target range without knowing the time relationship to the dose.
For the full pharmacokinetics of the SR-T3 serum curve and what it means for dosing decisions, see the Sustained Release T3 Complete Guide. For SR-T3 reference standards with verified HPMC matrix and clean excipients, see our Wilson's SR-T3 Combo Kit.
The FT3:rT3 Ratio Connection
Free T3 as a standalone serum value captures the amount of active thyroid hormone available in circulation - but it does not capture how much of the T3 receptor pool is being blocked by reverse T3 at the same time. Two research subjects with identical Free T3 values of 3.8 pg/mL can have completely different functional thyroid status if their reverse T3 levels differ substantially.
This is why the FT3:rT3 ratio matters as a complement to the absolute Free T3 value. The ratio divides Free T3 (in pg/mL) by reverse T3 (in ng/dL) and produces a single number that captures the competitive balance between the activating and inhibitory signals at the T3 receptor. The research-community target ratio is greater than or equal to 20:
| FT3:rT3 ratio | Research-community interpretation |
|---|---|
| > 20 | Excellent - active T3 signal dominates receptor pool |
| 15-20 | Adequate - low-grade rT3 elevation possible |
| 10-15 | Borderline rT3 dominance |
| < 10 | rT3 dominance - functional hypothyroidism likely |
A research subject with Free T3 at 3.8 pg/mL and reverse T3 at 12 ng/dL has a ratio of 31.7 - excellent active signal. The same Free T3 of 3.8 pg/mL with reverse T3 at 28 ng/dL produces a ratio of 13.6 - borderline rT3 dominance, with active signaling significantly attenuated despite what appears to be an adequate Free T3 value.
This distinction is why pursuing the upper-third Free T3 target while ignoring the rT3 concurrent value can produce a misleading picture of protocol success. Free T3 can appear optimal while the receptor environment remains dominated by its competitive inhibitor.
For the complete mechanistic background on reverse T3, the clinical conditions that drive it upward, and the Wilson's WT3 cyclic protocol for clearing rT3 dominance, see Reverse T3: The Complete Guide to rT3, FT3:rT3 Ratio, and How to Clear It. To calculate your ratio from lab values with automatic unit conversion, use the FT3:rT3 Ratio Calculator.
Free T3 Optimal Range Reference
View Free T3 ranges discussed in research forums
| Context | Free T3 target | Notes |
|---|---|---|
| Lab reference range (US) | 2.0-4.4 pg/mL | Population-derived, not symptom-derived |
| Lab reference range (SI) | 3.1-6.8 pmol/L | Same range, different units |
| Lower-symptom zone | Below 3.0 pg/mL | Higher symptom prevalence in research surveys |
| Research-community optimal | 3.6-4.4 pg/mL | Upper third of standard range |
| Wilson's WT3 peak (intentional) | 6-8 pg/mL | Supraphysiologic by design during up-titration |
| Wilson's WT3 maintenance (post-taper) | 3.6-4.4 pg/mL | Same as research-community optimal |
| Maintenance protocol target | 3.6-4.4 pg/mL | Upper third without cyclic excursion |
Time of draw matters: peak measurements (4-6h post-dose) read higher than trough measurements (12+h post-dose).
What "Free T3 Too Low" Means in the Research Framework
When a research subject on an SR-T3 protocol has Free T3 below 3.0 pg/mL at a peak draw - well below the upper-third target and near the lower portion of the reference range - the most useful next question is not "do I need a higher dose?" but "which of the mechanism-based explanations for T3 non-response applies here?"
The bioenergetic research community has identified six distinct explanations for inadequate Free T3 response to SR-T3 dosing:
- Dose genuinely too low - the most obvious possibility, but titration should be confirmed against both peak and trough draws before concluding this.
- Reverse T3 dominance - Free T3 may be entering the circulation but getting blocked at the receptor by a high rT3 load. The FT3:rT3 ratio reveals this pattern; the absolute Free T3 value alone does not.
- T3-to-T2 conversion bottleneck - the downstream conversion of T3 to 3,5-T2 (diiodothyronine) at the mitochondrial level may be impaired by DIO1 dysfunction, leaving mitochondrial cytochrome c oxidase under-activated even when serum Free T3 is adequate.
- Adrenal dysfunction - insufficient cortisol availability blunts the downstream response to T3 signaling; Free T3 can be adequate while the adrenal-thyroid interaction fails to produce the expected energy and temperature response.
- Iron deficiency - ferritin below approximately 50-70 ng/mL consistently impairs T3 receptor responsiveness; adequate Free T3 in an iron-deficient context does not translate to adequate receptor activation.
- Autoimmune flare - active Hashimoto's inflammation creates a localized tissue environment that attenuates thyroid signaling independent of circulating Free T3 levels.
Each explanation has a different diagnostic signal and a different corrective intervention. For the full diagnostic decision tree and the research-community approach to each explanation, see Why Isn't My T3 Working? The Six Research-Community Explanations for T3 Non-Response.
What Research Has and Hasn't Established
The evidence landscape around Free T3 optimization is layered. It is worth being precise about what is established, what is hypothesis, and what is definitively outside mainstream guidelines.
Established:
Free T3 laboratory reference ranges are population-derived and do not incorporate symptom-resolution criteria - this is a methodological fact, well-documented in the laboratory medicine literature. Reverse T3 modulates effective T3 signaling at the receptor level through competitive binding at the T3 receptor - this is mechanistically well-characterized. Time-of-draw relative to SR-T3 dosing materially affects measured Free T3 values - the Tmax of SR-T3 at 4-6 hours post-dose and the declining serum curve thereafter are documented in pharmacokinetic studies. The Wilson's WT3 protocol intentionally produces supraphysiologic Free T3 during the up-titration phase - this is explicit in the protocol's design rationale.
Hypothesis:
The upper-third Free T3 target as the research-community optimal range is a working hypothesis grounded in receptor saturation arguments. The mechanism is coherent: higher Free T3 should produce greater T3 receptor occupancy, and higher occupancy should produce more complete thyroid signaling. The connection between higher Free T3 and better symptom outcomes for research subjects with prior rT3 dominance is consistent with self-reported forum data. What does not exist is a randomized controlled trial comparing upper-third versus lower-third Free T3 targets with symptom resolution as the primary endpoint. The upper-third framework is the best available research-community working target, not a validated clinical standard.
Not endorsed by mainstream endocrinology:
Both the upper-third Free T3 targeting approach and the supraphysiologic Wilson's WT3 peaks during cyclic up-titration operate outside mainstream endocrinology guidelines. Mainstream guidance generally considers any Free T3 value within the lab reference range as acceptable, does not recognize the FT3:rT3 ratio as a standard clinical target, and does not endorse intentionally supraphysiologic T3 dosing. Research subjects pursuing these protocols are operating in a research-community context that is distinct from standard-of-care thyroid management.
Frequently Asked Questions
What is the optimal Free T3 range?
The bioenergetic research community targets the upper third of the standard laboratory reference range: approximately 3.6-4.4 pg/mL in conventional US units, or 5.6-6.8 pmol/L in SI units. This positioning is based on receptor saturation arguments and symptom-resolution patterns reported in research forums, not on RCT validation. Mainstream endocrinology does not distinguish an "optimal" sub-range within the reference interval.
Why is "normal" Free T3 not always enough?
Because the lab reference range is population-derived, not symptom-derived. The standard reference range captures the 2.5th to 97.5th percentile of an apparently healthy population, which includes subclinically hypothyroid individuals. A Free T3 value at 2.2 pg/mL is "normal" by this construction even if it is associated with ongoing hypothyroid symptoms in a given individual. The research-community framework looks at where within the range a value sits, not just whether it falls inside the stated boundaries.
What does Free T3 too low mean?
In the research-community framework, Free T3 consistently below 3.0 pg/mL on peak draws (4-6 hours post-dose) despite an adequate titration schedule suggests one of six explanations: dose genuinely insufficient, reverse T3 dominance blocking receptor activation, T3-to-T2 conversion bottleneck, adrenal dysfunction, iron deficiency, or autoimmune flare. The six-explanation framework in this post covers the diagnostic approach for each.
What should my Free T3 be on slow release T3?
On a maintenance SR-T3 protocol, research-community convention targets 3.6-4.4 pg/mL on a peak draw (4-6 hours post-dose). On the Wilson's WT3 cyclic protocol during active up-titration, Free T3 values of 6-8 pg/mL or higher are expected and are by design. The time of draw relative to the dose matters substantially - a trough draw (12+ hours post-dose) will read significantly lower than a peak draw at the same dose.
Is Wilson's WT3 supposed to push Free T3 above the lab range?
Yes, intentionally. The Wilson's WT3 cyclic protocol is designed to produce transient supraphysiologic Free T3 (often 6-12 pg/mL, above the standard 2.0-4.4 pg/mL range) during the up-titration phase. This supraphysiologic saturation is the mechanism by which the protocol clears reverse T3 dominance - it overwhelms competitive inhibition at the T3 receptor and suppresses the DIO3 enzyme that produces reverse T3. After the protocol's three-week temperature-sustainment criterion is met and the wean-down is completed, Free T3 settles back toward the upper-third maintenance target.
Does the time I get my labs drawn affect Free T3?
Significantly, on SR-T3. The serum peak for SR-T3 occurs 4-6 hours post-dose. A blood draw at that window captures the highest Free T3 the dose produces. A draw at 12+ hours captures the trough - which can be 20-40% lower than the peak. This means a research subject drawing labs at a standard 8 AM appointment after a 9 PM prior dose is capturing an approximately 11-hour post-dose trough, not the peak. Comparing a trough measurement directly to the upper-third peak target produces a misleading picture of whether the dose is adequate.
What is the FT3 to rT3 ratio?
The FT3:rT3 ratio divides your Free T3 value (in pg/mL) by your reverse T3 value (in ng/dL). The resulting ratio captures the competitive balance at the T3 receptor between the activating signal (Free T3) and the inhibitory signal (rT3). Research-community target: ratio of 20 or above. Values below 15 suggest meaningful rT3 interference; values below 10 suggest rT3 dominance. The FT3:rT3 Ratio Calculator handles unit conversions automatically.
Should I aim for upper-third Free T3?
For research-context SR-T3 protocols, the upper-third target (3.6-4.4 pg/mL on a peak draw) is the most commonly referenced symptom-resolution zone in bioenergetic thyroid research discussions. It is a working framework target, not a validated clinical standard. Whether it is the appropriate target for a given research subject depends on the concurrent rT3 load, the time of draw relative to dosing, the protocol context (cyclic vs maintenance), and cofactor status. Free T3 in isolation is an incomplete picture - the FT3:rT3 ratio and basal body temperature are the complementary markers that the research community uses alongside it.
Closing Note
Free T3 interpretation in the research-community context requires three coordinates, not one: the absolute value relative to the upper-third target (3.6-4.4 pg/mL), the time of draw relative to the SR-T3 dose (peak vs trough), and the concurrent FT3:rT3 ratio (target 20 or above). Any one of those data points in isolation can produce a misleading read on whether the protocol is working as intended.
The complete SR-T3 dosing and troubleshooting framework - starting dose, titration tempo, timing decisions, food interactions, missed-dose protocol, and the six explanations for non-response - is in Slow Release T3 Dosing and Troubleshooting: The Complete 2026 Research Guide. SR-T3 reference standards with verified HPMC matrix formulation are available in the Wilson's SR-T3 Combo Kit. For the full SR-T3 catalog, see our research compound catalog.